Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154675 | 0.72 | CHRNB2 (0.32) | — | |
| SCHEMBL13154670 | 0.70 | CHRNB2 (0.33) | — | |
| SCHEMBL13154669 | 0.69 | PKM (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13154662 | 0.67 | CHRNB2 (0.33) | — | |
| SCHEMBL30544820 | 0.66 | PRKCI (0.31) | — | |
| SCHEMBL13154645 | 0.66 | LMNA (0.52) | CHRM1 | |
| SCHEMBL7375651 | 0.66 | MAPT (0.52) | — | |
| SCHEMBL28760469 | 0.66 | PRKCI (0.31) | — | |
| SCHEMBL16416509 | 0.63 | — | — | |
| SCHEMBL31712925 | 0.61 | SRC (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101171252-B | Tetracyclic azapyrazinoindolines as 5-HT2 ligands | HOFFMANN LA ROCHE | 2011-06-01 | — | — | CN | disclosed |
| US-7547699-B2 | Tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity | HOFFMANN-LA ROCHE INC. (US) | 2009-06-16 | — | — | US | disclosed |
| CN-101171252-A | Tetracyclic azapyrazinoindolines as 5-HT2 ligands | HOFFMANN LA ROCHE (CH) | 2008-04-30 | — | — | CN | disclosed |
| US-20060252759-A1 | New tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252759-A1 | New tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity | HTR2C, HTR2A, HTR1B | CHRM2 168/4885CHRM4 274/4885CHRM5 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.